Navigation Links
Endo Pharmaceuticals to Announce Fourth Quarter and 2008 Full-Year Financial Results on February 27, 2009
Date:1/28/2009

CHADDS FORD, Pa., Jan. 28 /PRNewswire-FirstCall/ -- Endo Pharmaceuticals Inc. (Nasdaq: ENDP), will announce its fourth quarter and 2008 full-year financial results on February 27, 2009 and will host a conference call and webcast at 10:30 a.m. ET that day to discuss these results.

David P. Holveck, President and Chief Executive Officer, Nancy J. Wysenski, Chief Operating Officer and Blaine Davis, Vice President, Corporate Affairs will host the call.

Investors and other interested parties may call 866-543-6405 (domestic) or 617-213-8897 (international) and enter passcode 10990222. Please dial in 10 minutes prior to the scheduled start time.

A replay of the call will be available from February 27 at 1:00 p.m. ET until 12:00 a.m. ET on March 6 by dialing 888-286-8010 (domestic) or 617-801-6888 (international) and enter passcode 15067182.

A simultaneous webcast of the call may be accessed by visiting www.endo.com. In addition, a replay of the webcast will be available until 12:00 a.m. ET on March 6. The replay can be accessed by clicking on "Events" in the Investor Relations section of the website.

About Endo

Endo Pharmaceuticals is a specialty pharmaceutical company engaged in the research, development, sale and marketing of branded and generic prescription pharmaceuticals used primarily to treat and manage pain. Its products include LIDODERM(R), a topical patch to relieve the pain of postherpetic neuralgia; PERCOCET(R) and PERCODAN(R) tablets for the relief of moderate-to-moderately severe pain; FROVA(R) tablets for the acute treatment of migraine attacks with or without aura in adults; OPANA(R) tablets for the relief of moderate-to-severe acute pain where the use of an opioid is appropriate; OPANA(R) ER tablets for the relief of moderate-to-severe pain in patients requiring continuous, around-the-clock opioid treatment for an extended period of time; and VOLTAREN(R) gel, a nonsteroidal anti-inflammatory drug indicated for the relief of the pain of osteoarthritis of joints amenable to topical treatment. The company markets its branded pharmaceutical products to physicians in pain management, neurology, surgery, oncology, and primary care. More information, including this and past press releases of Endo Pharmaceuticals, is available at www.endo.com.


'/>"/>
SOURCE Endo Pharmaceuticals Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. XTL Biopharmaceuticals Announces Receipt of NASDAQ Notice of Delisting
2. XTL Biopharmaceuticals Provides Update on Potential Strategic Alternatives
3. Indevus Pharmaceuticals Announces Release of 2008 Annual Report
4. Amylin Pharmaceuticals Appoints Vincent Mihalik Senior Vice President, Sales and Marketing and Chief Commercial Officer
5. Rib-X Pharmaceuticals Announces Positive Phase 2 Study Results for Delafloxacin and a $25 Million Financing
6. MAP Pharmaceuticals Announces Completion of Enrollment in Phase 3 Clinical Trial of MAP0004 in Patients with Migraine
7. Axikin Pharmaceuticals Spins out of Actimis
8. BioMed Realty Trust Extends Leases With Vertex Pharmaceuticals Through 2015
9. Poniard Pharmaceuticals Announces Positive Tumor Response and Neuropathy Data from Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer
10. Cumberland Pharmaceuticals Appoints Lee Product Director
11. Genesis Pharmaceuticals Appoints KPMG to Help Develop a SOX 404 Compliance Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... ... March 23, 2017 , ... ... that exhibits both viscous and elastic characteristics when deformed, which is identical to ... properties to gently absorb compressive forces and return to its natural state along ...
(Date:3/23/2017)... March 23, 2017  Northwest Biotherapeutics (OTCQB: NWBO) ... immune therapies for solid tumor cancers, today announced ... financing it announced last Friday, March 17, 2017. ... institutional investors securities totaling 28,843,692 shares, comprised of ... 10,000,000 shares of Class C Warrants pre-funded at ...
(Date:3/23/2017)... 23, 2017  BioPharmX Corporation (NYSE MKT: BPMX), ... dermatology market, today reported financial results for the ... will provide an update on the company,s clinical ... "We are pleased to report that last ... said President Anja Krammer. "We achieved key clinical ...
(Date:3/23/2017)... NetworkNewsWire Editorial Coverage  ... Cancer remains one of the world,s ... systems, in terms of costs and resources. However, as the ... of innovative and efficient therapies that demonstrate higher chances of ... cancer treatments, a growing number of patients receiving immuno-oncology therapies ...
Breaking Biology Technology:
(Date:2/28/2017)... DORTMUND, Germany , February 28, 2017 ... ... Amsterdam from 14 to 16 March, ... to destination, and show how seamless travel is a real benefit ... Materna has added biometrics to their passenger touch point solutions to ...
(Date:2/26/2017)... 25, 2017  Securus Technologies, a leading provider ... public safety, investigation, corrections and monitoring, announces the ... "Too often, too many offenders return ... jails are trying to tackle this ongoing problem ... and family members. While significant steps are underway, Securus ...
(Date:2/21/2017)... and PORTLAND, Ore. , Feb. ... the Avamere Family of Companies (Avamere Health Services, Infinity ... a six-month research study that will apply the power ... at senior living and health centers. By analyzing data ... to gain insights into physical and environmental conditions, and ...
Breaking Biology News(10 mins):